Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 19, 2000

View Archived Issues

Maxygen and Scripps to collaborate in developing HIV vaccines

CGA-137053, a novel compound that blocks HIV replication by targeting the Tat protein

Phase II NeuroCell-PD trial for Parkinson's disease extended

Novel family of MTP inhibitors discovered at Janssen possess lipid-lowering properties

Wyeth-Ayerst obtains Alzheimer's drug discovery-related license

New HIV treatment option approved by FDA

Isoflavone-based bone resorption inhibitors presented by Chiesi in Bologna this week

Banyu's J-112287: a potent, selective and orally active ETA receptor antagonist

Highly potent motilin antagonists reported by Chugai

Antithrombotic development candidates profiled in Bologna by Mochida

Guanidine-based Na+/H+ inhibitors synthesized and tested at Sumitomo

Therapeutically useful M3/5-HT4 antagonists patented by major French lab

Newly issued patent covers series of guanylate cyclase activators designed by Aventis

SK reveals orally active compounds for depression which inhibit MAO

Sanofi-Synthelabo discloses synthesis and use of new alpha-azacyclomethylquinolines

ICAAC news: Janssen discovers novel fusion inhibitor with picomolar anti-RSV activity

Alphav integrin receptor antagonists claimed by Merck for inhibiting bone resorption

Novel chemokine receptor modulators revealed by Millennium

Research at Sanofi-Synthelabo leads to discovery of promising selective CB1 antagonist

Pseudo-proline-containing ciclosporin derivatives useful as prodrugs

Takeda presents newest antifungal candidates this week in Toronto

Combination 2ME2 and Taxotere trial begins

Glaxo Wellcome seeks new indication for Relenza

MetaPhore receives NIH grant for the study of novel pain treatments

Phase I Oncolym study begins for relapsed and refractory B-cell lymphoma

Almirall Prodesfarma commences launch of new triptan for migraine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.